What are the recommended dosing, contraindications, and monitoring parameters for tizanidine in an adult patient?

Tizanidine: Dosing, Contraindications, and Monitoring

Tizanidine should be initiated at 4 mg orally, titrated gradually in 2-4 mg increments every 6-8 hours as needed (maximum 36 mg/day in three divided doses), with mandatory liver function monitoring at baseline, 1,3, and 6 months, and is absolutely contraindicated with ciprofloxacin or fluvoxamine. 1

Mechanism and Clinical Profile

Tizanidine is an α2-adrenergic receptor agonist and centrally acting spasmolytic agent, structurally related to clonidine but with fewer cardiovascular effects 2. It demonstrates linear dose-proportional pharmacokinetics with peak effects at 1-2 hours and duration of 3-6 hours 1, 3.

Dosing Algorithm

Initial Dosing:

• Start at 4 mg orally as a single dose 1
• Assess response and tolerability over 6-8 hours

Titration Strategy:

• Increase by 2-4 mg increments to achieve optimal muscle tone reduction at tolerated dose 1
• Doses can be repeated every 6-8 hours, maximum 3 doses per 24 hours 1
• Maximum daily dose: 36 mg (though most patients respond to 24 mg/day or less) 1

Critical Dosing Caveat: The evidence base for single doses >8 mg and daily doses >24 mg is limited—only ~75 patients have been studied long-term at these higher doses 1. There is essentially no experience with repeated single daytime doses >12 mg 1.

Food Effects: Food significantly alters tizanidine pharmacokinetics. Switching between fed and fasted states can cause increased adverse events or altered onset of action 1. Maintain consistent administration relative to meals.

Absolute Contraindications

Do not prescribe tizanidine with:

• Ciprofloxacin - causes profound reduction in tizanidine clearance 2
• Fluvoxamine - causes profound reduction in tizanidine clearance 2

Relative Contraindications and High-Risk Populations

Avoid or use extreme caution in:

• Hepatic dysfunction - risk of toxic hepatic effects 1
• Renal dysfunction - significant sedative and hypotensive effects 2
• Elderly patients - increased sensitivity to sedation and hypotension 2
• Patients on antihypertensive therapy - additive hypotensive effects 1, 4
• Patients on other α2-adrenergic agonists - should not be combined 1

Drug Interactions Requiring Dose Adjustment

CYP1A2 inhibitors cause significant hypotension, bradycardia, and sedation 2:

• Oral contraceptives
• Acyclovir
• Amiodarone
• Verapamil
• Mexiletine
• Propafenone
• Cimetidine
• Famotidine

Synergistic hypotensive effects with:

• ACE inhibitors 4
• Angiotensin receptor blockers 4
• Beta-blockers 4

Alcohol: Concomitant use dramatically increases CNS depression and hypotension risk, including syncope 5. Counsel patients to abstain from alcohol.

Mandatory Monitoring Parameters

Liver Function Tests:

• Baseline ALT/AST before initiation 1
• 1 month after starting 1
• 3 months after starting 1
• 6 months after starting 1
• Periodically thereafter based on clinical status 1

Rationale: ~5% of patients develop transaminase elevations >3x upper limit of normal 1. Three deaths from liver failure have been reported, including cases of multilobular necrosis and fulminant hepatic failure 1.

Cardiovascular Monitoring:

• Blood pressure and heart rate before each dose advancement 1
• Monitor for orthostatic hypotension, particularly when moving from supine to upright 1
• Two-thirds of patients on 8 mg experience 20% reduction in BP within 1 hour, peaking at 2-3 hours 1

Mental Status:

• Screen for hallucinations/psychotic symptoms, particularly in first 6 weeks 1
• 3% of patients develop formed visual hallucinations or delusions 1

Common Adverse Effects

Dose-dependent effects:

• Sedation (48% of patients; 10% severe) - peaks in first week of titration 1, 6
• Dry mouth (xerostomia) - very common 6, 7
• Drowsiness/dizziness - 92% at 16 mg dose reported drowsiness 1
• Hypotension/bradycardia - dose-related, monitor closely 1, 4

Advantage over alternatives: Subjective muscle weakness occurs less frequently than with baclofen or diazepam 6.

Discontinuation Protocol

Never stop abruptly in long-term users. 2

Withdrawal syndrome includes:

• Rebound tachycardia
• Hypertension
• Hypertonia (increased muscle tone)

Taper slowly over several days to weeks when discontinuing chronic therapy 2.

Perioperative Management

Continue tizanidine through the day of surgery, including the morning dose 2. Abrupt discontinuation risks withdrawal symptoms that can complicate perioperative management.

Clinical Efficacy Context

Tizanidine reduces mean muscle tone scores by 21-37% versus 4-9% for placebo 6. It demonstrates efficacy comparable to baclofen (60-82% vs 60-65% improvement) with superior tolerability 6. The narrow therapeutic index and high interpatient variability necessitate individualized dose titration over 2-4 weeks 3, 6.